JP7838765B2 - 腹膜障害用の医薬組成物 - Google Patents

腹膜障害用の医薬組成物

Info

Publication number
JP7838765B2
JP7838765B2 JP2023580334A JP2023580334A JP7838765B2 JP 7838765 B2 JP7838765 B2 JP 7838765B2 JP 2023580334 A JP2023580334 A JP 2023580334A JP 2023580334 A JP2023580334 A JP 2023580334A JP 7838765 B2 JP7838765 B2 JP 7838765B2
Authority
JP
Japan
Prior art keywords
residue
peritoneal
group
compound
peritonitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023580334A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023153507A1 (https=
Inventor
和雄 北村
正司 水野
恒秀 金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miyazaki NUC
Tokai National Higher Education and Research System NUC
Original Assignee
University of Miyazaki NUC
Tokai National Higher Education and Research System NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miyazaki NUC, Tokai National Higher Education and Research System NUC filed Critical University of Miyazaki NUC
Publication of JPWO2023153507A1 publication Critical patent/JPWO2023153507A1/ja
Application granted granted Critical
Publication of JP7838765B2 publication Critical patent/JP7838765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023580334A 2022-02-14 2023-02-13 腹膜障害用の医薬組成物 Active JP7838765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022020346 2022-02-14
JP2022020346 2022-02-14
PCT/JP2023/004731 WO2023153507A1 (ja) 2022-02-14 2023-02-13 腹膜障害用の医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2023153507A1 JPWO2023153507A1 (https=) 2023-08-17
JP7838765B2 true JP7838765B2 (ja) 2026-04-01

Family

ID=87564559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580334A Active JP7838765B2 (ja) 2022-02-14 2023-02-13 腹膜障害用の医薬組成物

Country Status (2)

Country Link
JP (1) JP7838765B2 (https=)
WO (1) WO2023153507A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038348A (ja) 1998-05-21 2000-02-08 Nissho Corp アルブミン含有腹膜透析液
WO2018181638A1 (ja) 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2021201271A1 (ja) 2020-04-02 2021-10-07 国立大学法人宮崎大学 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
WO2022030580A1 (ja) 2020-08-06 2022-02-10 国立大学法人宮崎大学 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038348A (ja) 1998-05-21 2000-02-08 Nissho Corp アルブミン含有腹膜透析液
WO2018181638A1 (ja) 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2021201271A1 (ja) 2020-04-02 2021-10-07 国立大学法人宮崎大学 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
WO2022030580A1 (ja) 2020-08-06 2022-02-10 国立大学法人宮崎大学 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLEMENTI, G., et al.，Antiinflammatory activity of adrenomedullin in the acetic acid peritonitis in rats，Life Sciences，1999年，Vol.65, No.15，pp.PL203-PL208
KUROISHI, N., et al.，Development of a novel human adrenomedullin derivative: human serum albumin-conjugated adrenomedullin，J. Biochem.，2021年，Vol.170, No.4，pp.445-451，DOI:10. 1093/jb/mvab057

Also Published As

Publication number Publication date
WO2023153507A1 (ja) 2023-08-17
JPWO2023153507A1 (https=) 2023-08-17

Similar Documents

Publication Publication Date Title
US20230120030A1 (en) Long-Acting Adrenomedullin Derivatives
JP7566859B2 (ja) グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針
CN102718858B (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
ES2615484T3 (es) Composiciones medicinales que contienen grelina
JP4067058B2 (ja) Ｐｅｇ化ｈｇｆ
US9610318B2 (en) Peptides for promoting angiogenesis and use thereof
JP4255515B2 (ja) 安定化された成長ホルモン処方物およびその製造方法
JP2001500893A (ja) インスリンｃ―ペプチド
US20200222548A1 (en) Synthetic bioconjugates
CN102643339A (zh) 一种glp-1类似物、制备方法及其应用
KR20090130044A (ko) Ｇｈｒｈ 분자의 약제 제형
KR100465222B1 (ko) 평활근세포증식억제활성을갖는조직인자응고계인히비터(tfpi)-유래펩티드
JP4249025B2 (ja) ドライアイおよびドライアイを伴う疾病の治療剤
CN105451756A (zh) 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
EP3856767B1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
JP7838765B2 (ja) 腹膜障害用の医薬組成物
EP0189673B1 (en) Stable growth hormone releasing factor preparation
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
KR20080028981A (ko) Ｇｌｐ-1 약학 조성물
US5679771A (en) Method for treating intestinal diseases
JP3820607B2 (ja) アンチトロンビン−ｉｉｉの液状製剤およびその保存安定化方法
JP3034032B2 (ja) 腸疾患用薬剤
WO2013158959A1 (en) Compositions and methods for treatment of graft-versus-host disease
JPWO1996032960A1 (ja) 虚血性疾患の予防及び／又は治療剤
RU2008125167A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240607

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260311

R150 Certificate of patent or registration of utility model

Ref document number: 7838765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150